Innova Captab Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Innova Captab Limited Pharmaceutical Export Portfolio Dataset — 12 Products, $55.2M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Innova Captab Limited — Pharmaceutical Exporter Profile (2026) | 12 Products, $55.2M Trade | TransData Nexus

Innova Captab Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $55.2M Total Trade · DGFT Verified

Innova Captab Limited is an Indian pharmaceutical exporter with a total trade value of $55.2M across 12 products in 6 therapeutic categories. Based on 1,322 verified export shipments from Indian Customs (DGFT) records, Innova Captab Limited is the #1 Indian exporter in 1 product including Ceftriaxone. Top exports include Ceftriaxone ($30.0M), Artemether ($16.2M), Cefuroxime ($2.8M).

Innova Captab Limited — Export Portfolio & Destination Treemap

Innova Captab Limited pharmaceutical export portfolio — 12 products across 6 therapeutic categories. Source: Indian Customs (DGFT).

Who is Innova Captab Limited? — Company Overview & Market Position

Innova Captab Limited, established in 2005, is an integrated pharmaceutical company headquartered in Panchkula, Haryana, India. The company operates across the entire pharmaceutical value chain, encompassing research and development, manufacturing, distribution, marketing, and exports. Innova Captab Limited is publicly listed on the Bombay Stock Exchange under the ticker symbol 544067 and on the National Stock Exchange of India as INNOVACAP. As of March 13, 2026, the company has a market capitalization of approximately ₹40.83 billion. The company employs around 1,600 individuals, reflecting its substantial presence in the pharmaceutical industry. Innova Captab Limited's official website is innovacaptab.com.

What Does Innova Captab Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ceftriaxone$30.0M 2Artemether$16.2M

Product Portfolio — Top 12 by Export Value

Innova Captab Limited exports 12 pharmaceutical products across 6 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ceftriaxone	Advanced Antibiotics	$30.0M	600	10.5%	1
2	Artemether	Antimalarial & Antiparasitic	$16.2M	324	1.8%	3
3	Cefuroxime	Advanced Antibiotics	$2.8M	172	2.2%	8
4	Domperidone	Gastrointestinal	$1.6M	33	5.6%	2
5	Pantoprazole	Gastrointestinal	$1.6M	33	0.1%	14
6	Esomeprazole	Gastrointestinal	$1.1M	21	0.2%	15
7	Cefpodoxime	Advanced Antibiotics	$590.9K	59	0.7%	9
8	Nifedipine	Cardiovascular	$381.6K	54	1.3%	13
9	Tinidazole	Advanced Antibiotics	$297.0K	15	1.6%	12
10	Dapagliflozin	Advanced Diabetes Medications	$200.0K	4	0.4%	13
11	Vildagliptin	Advanced Diabetes Medications	$200.0K	4	2.0%	5
12	Prednisolone	Respiratory	$150.0K	3	0.2%	11

Innova Captab Limited exports 12 pharmaceutical products across 6 therapeutic categories with a total export value of $55.2M. The company is the #1 Indian exporter in 1 product: Ceftriaxone. The top category is Advanced Antibiotics (61.1% of portfolio), followed by Antimalarial & Antiparasitic (29.4%), indicating a concentrated portfolio with the top 5 products accounting for 94.8% of total export value.

Innova Captab Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Innova Captab Limited operates five state-of-the-art manufacturing facilities across India, each specializing in different pharmaceutical products. These facilities are located in Baddi (Himachal Pradesh), Dehradun (Uttarakhand), Taloja (Maharashtra), and Kathua (Jammu). The Kathua facility, which commenced commercial production in January 2025, includes four dedicated manufacturing blocks: General, Cephalosporin, Penicillin, and Penum. This expansion enhances the company's production capacity and product range, enabling the manufacture of oral solid dosages, dry powder injectables, dry syrups, BFS, large volume parenterals, and respiratory respule products. The facilities are compliant with WHO-GMP, EU-GMP, and other key certifications, ensuring adherence to international quality standards.

3Key Leadership

The leadership team at Innova Captab Limited is headed by Managing Director and CEO Vinay Lohariwala, who has been instrumental in driving the company's growth and strategic direction. Lokesh Bhasin serves as the Chief Financial Officer, overseeing the company's financial operations and strategic financial planning. Ayush Garg holds the position of Head of Investor Relations, managing communications with investors and stakeholders. The company's leadership is further supported by a team of experienced professionals dedicated to various functions, contributing to its operational efficiency and market presence.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Innova Captab Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Innova Captab Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals from various international regulatory authorities, facilitating the export of its pharmaceutical products to these regions. In January 2025, Innova Captab announced the commencement of commercial production at its Kathua, Jammu facility, which is compliant with WHO-GMP and EU-GMP standards, enhancing its capability to meet the stringent requirements of these markets. The company's adherence to international quality standards and its robust manufacturing capabilities have enabled it to secure approvals and maintain a strong market presence in these regulated markets.

2Emerging Markets

Innova Captab Limited has strategically expanded its footprint into emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's commitment to quality and compliance with international standards has facilitated the registration of its products with various health authorities in these regions. By obtaining WHO prequalification and other relevant certifications, Innova Captab has enhanced its ability to access and serve these markets effectively. This expansion aligns with the company's strategic vision to diversify its market presence and leverage growth opportunities in emerging economies.

Innova Captab Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Innova Captab Limited has made significant strides in the US market, with its manufacturing facilities registered with the US Food and Drug Administration (FDA). The company has filed multiple Abbreviated New Drug Applications (ANDAs), seeking approval for various generic formulations. Additionally, Innova Captab has submitted Drug Master Files (DMFs) to the FDA, providing detailed information about the manufacturing processes and quality controls of its products. The company's facilities have undergone FDA inspections, and it has maintained a positive inspection history, reflecting its commitment to adhering to stringent regulatory standards. These efforts underscore Innova Captab's dedication to ensuring the safety, efficacy, and quality of its products in the US market.

2WHO & EU GMP

Innova Captab Limited's manufacturing facilities are compliant with Good Manufacturing Practices (GMP) standards set by the World Health Organization (WHO) and the European Union (EU). The company's commitment to quality is evident in its adherence to these international standards, ensuring that its products meet the rigorous requirements of global markets. The WHO prequalification and EU GMP certifications enhance the company's credibility and facilitate the registration and acceptance of its products in various international markets. These certifications reflect Innova Captab's dedication to maintaining high-quality manufacturing processes and its focus on delivering safe and effective pharmaceutical products worldwide.

Innova Captab Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Innova Captab Limited operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products across overlapping therapeutic categories. The company's top competitors include established pharmaceutical companies with a global presence and a diverse product portfolio. In the Advanced Antibiotics category, Innova Captab's leading product, Ceftriaxone, holds a market share of 10.5%, positioning it as a significant player in this segment. In the Antimalarial & Antiparasitic category, Artemether, with a market share of 1.8%, and in the Gastrointestinal category, Pantoprazole, with a market share of 0.1%, contribute to the company's competitive positioning. The company's focus on quality, regulatory compliance, and strategic market expansion enhances its competitiveness in these therapeutic areas.

2Key Differentiators

Innova Captab Limited's key differentiators include its comprehensive product portfolio, encompassing 12 products across six therapeutic categories, with a strong emphasis on Advanced Antibiotics, Antimalarial & Antiparasitic, and Gastrointestinal segments. The company's leading position in the Ceftriaxone market, with a 10.5% market share, underscores its strength in the Advanced Antibiotics category. Additionally, Innova Captab's commitment to quality is demonstrated through its compliance with WHO-GMP and EU-GMP standards, ensuring that its products meet international quality benchmarks. The company's strategic expansion into both regulated and emerging markets further differentiates it, allowing for a diversified revenue stream and reduced market concentration risk.

Buyer Due Diligence Brief — Evaluating Innova Captab Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Innova Captab Limited has demonstrated a strong track record in manufacturing and exporting pharmaceutical products, with a total export value of $55.2 million USD and 1,322 shipments across 12 products in six therapeutic categories. The company's portfolio concentration, with the top five products accounting for

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Innova Captab Limited

How many pharmaceutical products does Innova Captab Limited export from India?

Innova Captab Limited exports 12 pharmaceutical products across 6 therapeutic categories. The top exports are Ceftriaxone ($30.0M), Artemether ($16.2M), Cefuroxime ($2.8M), Domperidone ($1.6M), Pantoprazole ($1.6M). Total export value is $55.2M.

What is Innova Captab Limited's total pharmaceutical export value?

Innova Captab Limited's total pharmaceutical export value is $55.2M, based on 1,322 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Innova Captab Limited the #1 Indian exporter?

Innova Captab Limited is the #1 Indian exporter in 1 products: Ceftriaxone (10.5% market share).

What therapeutic categories does Innova Captab Limited cover?

Innova Captab Limited exports across 6 therapeutic categories. The largest are Advanced Antibiotics (61.1%, 4 products), Antimalarial & Antiparasitic (29.4%, 1 products), Gastrointestinal (7.9%, 3 products).

Get Full Innova Captab Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.